Physician profile
Manish Thapar
NPI 1124245162
$66,106.70
in general payments reported to CMS, 2019-2025
20 companies · $31K in 2025
The $31K reported for 2025 was more than what 87% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $9,849 · 2021: $7,347 · 2022: $8,414 · 2023: $5,976 · 2024: $3,161 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,925 · Honoraria: $7,785 · Travel and Lodging: $6,253 · Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,802.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,925.00 |
| Honoraria | $7,785.00 |
| Travel and Lodging | $6,252.86 |
| Food and Beverage | $1,205.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $37,079.35 | 2019-2025 | Givlaari |
| Recordati_rare_diseases_inc. | $19,764.32 | 2022-2025 | Panhematin |
| Tanabe Pharma America, INC. | $3,475.00 | 2022 | |
| Orphalan INC | $3,000.00 | 2024 | Cuvrior |
| Alexion Pharmaceuticals, INC. | $1,172.50 | 2022 | |
| Gilead Sciences, INC. | $610.04 | 2019-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $236.81 | 2024-2025 | Resmetirom, Rezdiffra |
| Abbvie INC. | $158.66 | 2019-2024 | Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.43 | 2019-2022 | |
| Mitsubishi Tanabe Pharma Development America, INC. | $115.26 | 2020 | |
| Novo Nordisk INC | $88.29 | 2025 | |
| Mallinckrodt Hospital Products INC. | $49.40 | 2025 | Terlivaz |
| Eisai INC. | $37.35 | 2019-2020 | |
| Haemonetics Corporation | $36.87 | 2021 | |
| Intercept Pharmaceuticals, INC. | $27.87 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $27.43 | 2019-2020 | |
| Dynavax Technologies Corporation | $21.32 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $19.97 | 2020 | |
| Mirum Pharmaceuticals, INC. | $16.56 | 2025 | Cholbam, Chenodal, Livmarli |
| E.R. Squibb & Sons, L.L.C. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Thapar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.